These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 10914739

  • 21. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model.
    Wacheck V, Heere-Ress E, Halaschek-Wiener J, Lucas T, Meyer H, Eichler HG, Jansen B.
    J Mol Med (Berl); 2001 Oct; 79(10):587-93. PubMed ID: 11692156
    [Abstract] [Full Text] [Related]

  • 22. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L, Ayyanar K, Kornblum N, Castanotto D, Rossi J, Wu S, Lai J, Brown BD, Popova N, Miller P, McMicken H, Chen Y, Stein CA.
    Clin Cancer Res; 2006 Aug 15; 12(16):4940-8. PubMed ID: 16914583
    [Abstract] [Full Text] [Related]

  • 23. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A.
    Clin Cancer Res; 2002 Apr 15; 8(4):1277-83. PubMed ID: 11948143
    [Abstract] [Full Text] [Related]

  • 24. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X, Ding L, Xu Y, Wang Y, Ping Q.
    Int J Pharm; 2009 May 21; 373(1-2):116-23. PubMed ID: 19429296
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE.
    J Pharmacol Exp Ther; 1997 Apr 21; 281(1):420-7. PubMed ID: 9103525
    [Abstract] [Full Text] [Related]

  • 26. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
    Joyner DE, Albritton KH, Bastar JD, Randall RL.
    J Orthop Res; 2006 Mar 21; 24(3):474-80. PubMed ID: 16450387
    [Abstract] [Full Text] [Related]

  • 27. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC.
    J Clin Oncol; 2005 May 20; 23(15):3404-11. PubMed ID: 15824414
    [Abstract] [Full Text] [Related]

  • 28. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T.
    Int J Oncol; 2003 Apr 20; 22(4):875-81. PubMed ID: 12632082
    [Abstract] [Full Text] [Related]

  • 29. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
    Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D.
    Cancer Res; 1992 Dec 15; 52(24):6774-81. PubMed ID: 1458465
    [Abstract] [Full Text] [Related]

  • 30. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, Pliquett U, Neumann E, Zeuzem S.
    Oncogene; 2003 Jan 09; 22(1):69-80. PubMed ID: 12527909
    [Abstract] [Full Text] [Related]

  • 31. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2001 Aug 09; 7(8):2537-44. PubMed ID: 11489837
    [Abstract] [Full Text] [Related]

  • 32. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
    Dai G, Chan KK, Liu S, Hoyt D, Whitman S, Klisovic M, Shen T, Caligiuri MA, Byrd J, Grever M, Marcucci G.
    Clin Cancer Res; 2005 Apr 15; 11(8):2998-3008. PubMed ID: 15837754
    [Abstract] [Full Text] [Related]

  • 33. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV, Forté AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ.
    Anticancer Drugs; 2007 Nov 15; 18(10):1189-200. PubMed ID: 17893520
    [Abstract] [Full Text] [Related]

  • 34. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
    Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC.
    Clin Cancer Res; 2003 Jul 15; 9(7):2826-36. PubMed ID: 12855663
    [Abstract] [Full Text] [Related]

  • 35. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
    Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4185-91. PubMed ID: 15217956
    [Abstract] [Full Text] [Related]

  • 36. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts.
    Sakakibara T, Chen FA, Kida H, Kunieda K, Cuenca RE, Martin FJ, Bankert RB.
    Cancer Res; 1996 Aug 15; 56(16):3743-6. PubMed ID: 8706018
    [Abstract] [Full Text] [Related]

  • 37. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.
    Chi KC, Wallis AE, Lee CH, De Menezes DL, Sartor J, Dragowska WH, Mayer LD.
    Breast Cancer Res Treat; 2000 Oct 15; 63(3):199-212. PubMed ID: 11110054
    [Abstract] [Full Text] [Related]

  • 38. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V, Dasnois L, Lebtahi K, Collot F, Heylen N, Havaux N, Fernandez AM, Lobl TJ, Oliyai C, Nieder M, Shochat D, Yarranton GT, Trouet A.
    Cancer Res; 2002 Apr 15; 62(8):2327-31. PubMed ID: 11956091
    [Abstract] [Full Text] [Related]

  • 39. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
    Rait AS, Pirollo KF, Rait V, Krygier JE, Xiang L, Chang EH.
    Cancer Gene Ther; 2001 Oct 15; 8(10):728-39. PubMed ID: 11687896
    [Abstract] [Full Text] [Related]

  • 40. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR, Tang W, Rahman A, Dritschilo A, Ahmad I, Kasid UN, Gokhale PC.
    Int J Oncol; 2004 May 15; 24(5):1181-8. PubMed ID: 15067340
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.